Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (151-160 of 189) with videos related to

Pageof 19
Sort By:
BMC Immunology|July 20, 2005
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOTHolden T Maecker, James Moon, Sonny Bhatia, et al.
Genes, Chromosomes & Cancer|August 3, 2006
Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancersChristopher C Benz, Vita Fedele, Fan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerMary L Disis, Danelle R Wallace, Theodore A Gooley, et al.
Journal of Cancer Prevention|January 20, 2022
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: ReportAltaf Mohammed, Roderick H Dashwood, Sally Dickinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2010
A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102Lavakumar Karyampudi, Courtney Formicola, Courtney L Erskine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 2009
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigenLavakumar Karyampudi, Christopher J Krco, Kimberly R Kalli, et al.
Journal of the National Cancer Institute|September 11, 2019
Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast CancerJohannes F Fahrmann, Jody Vykoukal, Alia Fleury, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapySacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, et al.
JAMA Oncology|January 25, 2019
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor TrialMary L Disis, Matthew H Taylor, Karen Kelly, et al.
Pageof 19

Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
BMC Immunology|July 20, 2005
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOTHolden T Maecker, James Moon, Sonny Bhatia, et al.
Genes, Chromosomes & Cancer|August 3, 2006
Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancersChristopher C Benz, Vita Fedele, Fan Xu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerMary L Disis, Danelle R Wallace, Theodore A Gooley, et al.
Journal of Cancer Prevention|January 20, 2022
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: ReportAltaf Mohammed, Roderick H Dashwood, Sally Dickinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2010
A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102Lavakumar Karyampudi, Courtney Formicola, Courtney L Erskine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 21, 2002
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological TherapyUlrich Keilholz, Jeffrey Weber, James H Finke, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 2009
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigenLavakumar Karyampudi, Christopher J Krco, Kimberly R Kalli, et al.
Journal of the National Cancer Institute|September 11, 2019
Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast CancerJohannes F Fahrmann, Jody Vykoukal, Alia Fleury, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapySacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, et al.
JAMA Oncology|January 25, 2019
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor TrialMary L Disis, Matthew H Taylor, Karen Kelly, et al.
Pageof 19